KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Interest Expenses (2016 - 2022)

NovoCure's Interest Expenses history spans 9 years, with the latest figure at $2.2 million for Q2 2022.

  • For Q2 2022, Interest Expenses rose 137.02% year-over-year to $2.2 million; the TTM value through Mar 2023 reached $2.2 million, down 67.26%, while the annual FY2021 figure was $7.7 million, 37.05% down from the prior year.
  • Interest Expenses for Q2 2022 was $2.2 million at NovoCure, up from $1.7 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $4.9 million in Q1 2018 and bottomed at $940000.0 in Q2 2021.
  • The 5-year median for Interest Expenses is $2.4 million (2018), against an average of $2.5 million.
  • The largest annual shift saw Interest Expenses plummeted 64.08% in 2021 before it soared 137.02% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $2.2 million in 2018, then fell by 19.21% to $1.7 million in 2019, then soared by 87.22% to $3.3 million in 2020, then plummeted by 33.43% to $2.2 million in 2021, then increased by 2.44% to $2.2 million in 2022.
  • Per Business Quant, the three most recent readings for NVCR's Interest Expenses are $2.2 million (Q2 2022), $1.7 million (Q1 2022), and $2.2 million (Q4 2021).